Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

November 19, 2022 by Alan Khadavi

Nucala, Fasenra or Dupixent for Severe Eosinophilic Asthma?

With the advent of new biological medications for severe eosinophilic asthma, patients have improved significantly.  Approximately 10% of individuals with asthma have severe disease, and this accounts for most asthma related morbidity and mortality. Previously the mainstay of treatment was inhaled steroids and beta agonists. In patients with severe asthma who have high eosinophils (greater than 150 cells or greater than 300 cells depending on the study), Nucala, Fasenra and Dupixent have all been shown to decrease exacerbation rates, improve lung function and improve quality of life among individuals.

There are no head to head studies comparing Nucala, Fasenra or Dupixent for severe eosinophilic asthma. But a recent study published in The Journal of Allergy and Clinical Immunology; November 2022 titled “Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis”, the authors sought to compare these medications based on their safety and efficacy.

A total of 8 studies were included in this analysis for a total of 6461 patients.

All the biologics examined were associated with significant improvement of exacerbation rates compared to placebo, although the relative ranking of treatments varied according to eosinophil thresholds. The study authors noted minimal differences between the biologics, and all of them leading to a similar decrease in exacerbation rates. They also found that the differences in the safety and efficacy of nucala, fasenra and dupixent were relatively small. None of the biologics had a significant reduction in FEV1 (values on a Pulmonary Function Test), compared to each other.

All of them showed a greater response to therapy as the eosinophil count was higher. There was a greater effect in individuals with eosinophil counts >300 compared to the 150-299 range. They did find that Fasenra performed a bit better with the eosinophil count range of 150-299 cells compared to Dupixent and Nucala, but it was not statistically significant.

The ultimate choice of biologic for each patient would depend on multiple factors including costs, co-morbid conditions (i.e. nasal polyps, eczema) and timing of administration.

Other biologics not compared here are Cinqair which is dosed on weight and Tezspire, which does not require biomarker and is indicated for both eosinophilic and non-eosinophilic asthma.

In conclusion, the choice of biologics is diverse and you should speak to you doctor about which one would be right for you if you have uncontrolled severe eosinophilic asthma.

New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Fasenra (Benralizumab) for Severe Asthma

Asthma biologic agents (Xolair, Cinqair, Nucala, Fasenra, Dupixent)

Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)

Tezspire Tezepelumab for Severe Asthma

 

 

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page